Platinum Priority – Voiding DysfunctionEditorial by Barbara Padilla-Fernández and David Castro-Díaz on pp. 146–147 of this issueEfficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)
Editorial by Barbara Padilla-Fernández and David Castro-Díaz on pp. 146–147 of this issue
Under a Creative Commons license
open access
Keywords
Add-on therapy
Incontinence
Mirabegron
Overactive bladder
Solifenacin
Cited by (0)
© 2016 European Association of Urology. Published by Elsevier B.V.